New RSV mRNA vaccine enters first human safety tests

NCT ID NCT07418229

Not yet recruiting ⭐️ VACCINE ⭐️ Sponsor: Sinovac Biotech Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial will test the safety of a new RSV mRNA vaccine in 60 healthy adults aged 18 and older. Participants will receive either a low dose, high dose, or a placebo (saline) shot. The study aims to see if the vaccine causes any side effects, paving the way for larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RSV mRNA vaccine
What this could lead to: If successful, this could lead to a safe vaccine against RSV, a common respiratory virus that can be serious for older adults.
What could go wrong: This is a very early Phase 1 trial with only 60 participants, focused on safety, not effectiveness. The vaccine may not work or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MRNA VACCINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MRNA VACCINE RSV

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Qinxian Center for Disease Control and Prevention

Changzhi, Shanxi, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.